Literature DB >> 24382787

National trends in pancreatic cancer outcomes and pattern of care among Medicare beneficiaries, 2000 through 2010.

Yun Wang1, Deborah Schrag, Gabriel A Brooks, Francesca Dominici.   

Abstract

BACKGROUND: Pancreatic cancer is a major cause of morbidity and mortality in the Medicare population. Whether the health care burden of pancreatic cancer has changed over the last decade is unknown.
METHODS: The authors used Medicare data from 2000 to 2010 to identify beneficiaries aged ≥ 65 years who were hospitalized for the management of pancreatic cancer. Annual trends were estimated for the age-sex-race-adjusted initial hospitalization rate, the age-sex-race-comorbidity-adjusted 1-year mortality rate after initial hospitalization, age-sex-race-comorbidity-adjusted procedure rates, 1-year all-cause rehospitalizations after initial pancreatic cancer hospitalization, and mean inflation-adjusted Medicare payment for initial hospitalization.
RESULTS: A total of 130,728 patients had ≥ 1 hospitalizations for pancreatic cancer and were identified from 56,642,071 beneficiaries during the study period. The age-sex-race-adjusted rate of initial hospitalization for pancreatic cancer was 50 per 100,000 person-years in 2010, representing a 0.5% annual increase since 2000 (95% confidence interval [95% CI], 0.3%-0.7%). In the same period, the age-sex-race-comorbidity-adjusted 1-year mortality rate decreased by 4.4% (95% CI, 3.9%-4.9%), and the age-sex-race-comorbidity-adjusted surgical resection rate increased by 6.9% (95% CI, 6.4%-7.5%). The mean inflation-adjusted Medicare payment for the initial hospitalization decreased, from $14,118 in 2000 to $13,318 in 2010, and the number of 1-year all-cause rehospitalizations after the initial hospitalization increased from 0.75 per patient in 2000 to 0.82 per patient in 2009 (all P < .001).
CONCLUSIONS: For Medicare fee-for-service beneficiaries, initial pancreatic cancer hospitalization, surgical resection, and rehospitalization rates increased, but 1-year mortality rates declined over the last decade.
© 2013 American Cancer Society.

Entities:  

Keywords:  Medicare; hospitalization; mortality; outcomes; pancreatic cancer; trends

Mesh:

Year:  2013        PMID: 24382787      PMCID: PMC4019988          DOI: 10.1002/cncr.28537

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  24 in total

1.  Trends in hospital volume and operative mortality for high-risk surgery.

Authors:  Jonathan F Finks; Nicholas H Osborne; John D Birkmeyer
Journal:  N Engl J Med       Date:  2011-06-02       Impact factor: 91.245

2.  Oncology Practice Trends From the National Practice Benchmark, 2005 through 2010.

Authors:  Thomas R Barr; Elaine L Towle
Journal:  J Oncol Pract       Date:  2011-09       Impact factor: 3.840

3.  Trends in meat consumption in the USA.

Authors:  Carrie R Daniel; Amanda J Cross; Corinna Koebnick; Rashmi Sinha
Journal:  Public Health Nutr       Date:  2010-11-12       Impact factor: 4.022

4.  1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience.

Authors:  Jordan M Winter; John L Cameron; Kurtis A Campbell; Meghan A Arnold; David C Chang; Joann Coleman; Mary B Hodgin; Patricia K Sauter; Ralph H Hruban; Taylor S Riall; Richard D Schulick; Michael A Choti; Keith D Lillemoe; Charles J Yeo
Journal:  J Gastrointest Surg       Date:  2006-11       Impact factor: 3.452

5.  Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.

Authors:  Helmut Oettle; Stefan Post; Peter Neuhaus; Klaus Gellert; Jan Langrehr; Karsten Ridwelski; Harald Schramm; Joerg Fahlke; Carl Zuelke; Christof Burkart; Klaus Gutberlet; Erika Kettner; Harald Schmalenberg; Karin Weigang-Koehler; Wolf-Otto Bechstein; Marco Niedergethmann; Ingo Schmidt-Wolf; Lars Roll; Bernd Doerken; Hanno Riess
Journal:  JAMA       Date:  2007-01-17       Impact factor: 56.272

6.  Trends in the treatment and outcome of pancreatic cancer in the United States.

Authors:  Nancy N Baxter; Bryan A Whitson; Todd M Tuttle
Journal:  Ann Surg Oncol       Date:  2007-01-17       Impact factor: 5.344

7.  Providing cancer care to a graying and diverse cancer population in the 21st century: are we prepared?

Authors:  June M McKoy; Athena T Samaras; Charles L Bennett
Journal:  J Clin Oncol       Date:  2009-04-29       Impact factor: 44.544

8.  The epidemiology of pancreatic cancer in the United States: changes below the surface.

Authors:  Y H Shaib; J A Davila; H B El-Serag
Journal:  Aliment Pharmacol Ther       Date:  2006-07-01       Impact factor: 8.171

9.  Benchmarks for value in cancer care: an analysis of a large commercial population.

Authors:  Michael Kolodziej; J Russell Hoverman; Jody S Garey; Janet Espirito; Sheetal Sheth; Aimee Ginsburg; Marcus A Neubauer; Debra Patt; Barry Brooks; Charles White; Mark Sitarik; Roger Anderson; Roy Beveridge
Journal:  J Oncol Pract       Date:  2011-09       Impact factor: 3.840

10.  Risk adjustment of Medicare capitation payments using the CMS-HCC model.

Authors:  Gregory C Pope; John Kautter; Randall P Ellis; Arlene S Ash; John Z Ayanian; Lisa I Lezzoni; Melvin J Ingber; Jesse M Levy; John Robst
Journal:  Health Care Financ Rev       Date:  2004
View more
  3 in total

1.  Burden of in-hospital care in oesophageal cancer: national population-based study.

Authors:  G Linder; F Klevebro; D Edholm; J Johansson; M Lindblad; J Hedberg
Journal:  BJS Open       Date:  2021-05-07

2.  Meta‑analysis of current chemotherapy regimens in advanced pancreatic cancer to prolong survival and reduce treatment‑associated toxicities.

Authors:  Jie Chen; Linli Chen; Jianping Yu; Yanmei Xu; Xiaohui Wang; Ziqian Zeng; Ning Liu; Fan Xu; Shu Yang
Journal:  Mol Med Rep       Date:  2018-11-09       Impact factor: 2.952

3.  Decreased trend in hospital mortality from pancreatic cancer despite increase in number of hospital admissions.

Authors:  Sanjay Bhandari; Mubeen Khan Mohammed Abdul; Will Hollabaugh; Kanav Sharma; Douglas B Evans; Nalini Guda
Journal:  PLoS One       Date:  2018-07-18       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.